1
|
Gutierrez V, Kim-Vasquez D, Shum M, Yang Q, Dikeman D, Louie SG, Shirihai OS, Tsukamoto H, Liesa M. The mitochondrial biliverdin exporter ABCB10 in hepatocytes mitigates neutrophilic inflammation in alcoholic hepatitis. Redox Biol 2024; 70:103052. [PMID: 38290384 PMCID: PMC10844117 DOI: 10.1016/j.redox.2024.103052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Accepted: 01/19/2024] [Indexed: 02/01/2024] Open
Abstract
Acute liver failure caused by alcoholic hepatitis (AH) is only effectively treated with liver transplantation. Livers of patients with AH show a unique molecular signature characterized by defective hepatocellular redox metabolism, concurrent to hepatic infiltration of neutrophils that express myeloperoxidase (MPO) and form neutrophil extracellular traps (NETs). Exacerbated NET formation and MPO activity contribute to liver damage in mice with AH and predicts poor prognosis in AH patients. The identification of pathways that maladaptively exacerbate neutrophilic activity in liver could inform of novel therapeutic approaches to treat AH. Whether the redox defects of hepatocytes in AH directly exacerbate neutrophilic inflammation and NET formation is unclear. Here we identify that the protein content of the mitochondrial biliverdin exporter ABCB10, which increases hepatocyte-autonomous synthesis of the ROS-scavenger bilirubin, is decreased in livers from humans and mice with AH. Increasing ABCB10 expression selectively in hepatocytes of mice with AH is sufficient to decrease MPO gene expression and histone H3 citrullination, a specific marker of NET formation. These anti-inflammatory effects can be explained by ABCB10 function reducing ROS-mediated actions in liver. Accordingly, ABCB10 gain-of-function selectively increased the mitochondrial GSH/GSSG ratio and decreased hepatic 4-HNE protein adducts, without elevating mitochondrial fat expenditure capacity, nor mitigating steatosis and hepatocyte death. Thus, our study supports that ABCB10 function regulating ROS-mediated actions within surviving hepatocytes mitigates the maladaptive activation of infiltrated neutrophils in AH. Consequently, ABCB10 gain-of-function in human hepatocytes could potentially decrease acute liver failure by decreasing the inflammatory flare caused by excessive neutrophil activity.
Collapse
Affiliation(s)
- Vincent Gutierrez
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Molecular and Cellular Integrative Physiology, Interdepartmental Program, University of California, Los Angeles, CA, USA
| | - Doyeon Kim-Vasquez
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Michael Shum
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Qihong Yang
- Southern California Research Center for ALPD and Cirrhosis and Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Dante Dikeman
- Department of Clinical Pharmacy, School of Pharmacy, The University of Southern California, 1985 Zonal Avenue, Los Angeles, CA, 90089, USA
| | - Stan G Louie
- Department of Clinical Pharmacy, School of Pharmacy, The University of Southern California, 1985 Zonal Avenue, Los Angeles, CA, 90089, USA
| | - Orian S Shirihai
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Molecular and Cellular Integrative Physiology, Interdepartmental Program, University of California, Los Angeles, CA, USA
| | - Hidekazu Tsukamoto
- Southern California Research Center for ALPD and Cirrhosis and Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA
| | - Marc Liesa
- Institut de Biologia Molecular de Barcelona, IBMB, CSIC, Barcelona, Catalonia, Spain.
| |
Collapse
|
2
|
Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, Harvey M, Neveu B, Loehr J, Bergeron A, Fradet Y, Lacombe L, Riopel J, Latulippe É, Atallah C, Shum M, Lambert J, Pouliot F, Pelletier M, Audet‐Walsh É. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer. Mol Oncol 2023; 17:2109-2125. [PMID: 37086156 PMCID: PMC10552900 DOI: 10.1002/1878-0261.13441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 03/07/2023] [Accepted: 04/21/2023] [Indexed: 04/23/2023] Open
Abstract
The androgen receptor (AR) is an established orchestrator of cell metabolism in prostate cancer (PCa), notably by inducing an oxidative mitochondrial program. Intriguingly, AR regulates cytoplasmic isocitrate dehydrogenase 1 (IDH1), but not its mitochondrial counterparts IDH2 and IDH3. Here, we aimed to understand the functional role of IDH1 in PCa. Mouse models, in vitro human PCa cell lines, and human patient-derived organoids (PDOs) were used to study the expression and activity of IDH enzymes in the normal prostate and PCa. Genetic and pharmacological inhibition of IDH1 was then combined with extracellular flux analyses and gas chromatography-mass spectrometry for metabolomic analyses and cancer cell proliferation in vitro and in vivo. In PCa cells, more than 90% of the total IDH activity is mediated through IDH1 rather than its mitochondrial counterparts. This profile seems to originate from the specialized prostate metabolic program, as observed using mouse prostate and PDOs. Pharmacological and genetic inhibition of IDH1 impaired mitochondrial respiration, suggesting that this cytoplasmic enzyme contributes to the mitochondrial tricarboxylic acid cycle (TCA) in PCa. Mass spectrometry-based metabolomics confirmed this hypothesis, showing that inhibition of IDH1 impairs carbon flux into the TCA cycle. Consequently, inhibition of IDH1 decreased PCa cell proliferation in vitro and in vivo. These results demonstrate that PCa cells have a hybrid cytoplasmic-mitochondrial TCA cycle that depends on IDH1. This metabolic enzyme represents a metabolic vulnerability of PCa cells and a potential new therapeutic target.
Collapse
Affiliation(s)
- Kevin Gonthier
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Department of Molecular Medicine, Faculty of MedicineUniversité LavalQuébecCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
| | - Cindy Weidmann
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
| | - Line Berthiaume
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
| | - Cynthia Jobin
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Department of Molecular Medicine, Faculty of MedicineUniversité LavalQuébecCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
| | - Aurélie Lacouture
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Department of Molecular Medicine, Faculty of MedicineUniversité LavalQuébecCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
| | - Camille Lafront
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Department of Molecular Medicine, Faculty of MedicineUniversité LavalQuébecCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
| | - Mario Harvey
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
| | - Bertrand Neveu
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
- Oncology AxisCentre de recherche du CHU de Québec – Université LavalCanada
| | - Jérémy Loehr
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
| | - Alain Bergeron
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
- Oncology AxisCentre de recherche du CHU de Québec – Université LavalCanada
- Department of Surgery, Faculty of MedicineUniversité LavalQuébecCanada
| | - Yves Fradet
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
- Oncology AxisCentre de recherche du CHU de Québec – Université LavalCanada
- Department of Surgery, Faculty of MedicineUniversité LavalQuébecCanada
| | - Louis Lacombe
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
- Oncology AxisCentre de recherche du CHU de Québec – Université LavalCanada
- Department of Surgery, Faculty of MedicineUniversité LavalQuébecCanada
| | - Julie Riopel
- Anatomopathology Service, Department of Laboratory MedicineCHU de Québec – Université LavalCanada
| | - Éva Latulippe
- Department of PathologyCHU de Québec – Université LavalCanada
| | - Chantal Atallah
- Department of PathologyCHU de Québec – Université LavalCanada
| | - Michael Shum
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Department of Molecular Medicine, Faculty of MedicineUniversité LavalQuébecCanada
| | - Jean‐Philippe Lambert
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Department of Molecular Medicine, Faculty of MedicineUniversité LavalQuébecCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
- Big Data Research CenterUniversité LavalQuébecQCCanada
| | - Frédéric Pouliot
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
- Oncology AxisCentre de recherche du CHU de Québec – Université LavalCanada
- Department of Surgery, Faculty of MedicineUniversité LavalQuébecCanada
| | - Martin Pelletier
- Infectious and Immune Disease AxisCHU de Québec‐Université Laval Research CenterCanada
- ARThrite Research CenterUniversité LavalQuébecQCCanada
- Department of Microbiology‐Infectious Diseases and Immunology, Faculty of MedicineUniversité LavalQuébecQCCanada
| | - Étienne Audet‐Walsh
- Endocrinology – Nephrology Research AxisCHU de Québec‐Université Laval Research CenterCanada
- Department of Molecular Medicine, Faculty of MedicineUniversité LavalQuébecCanada
- Centre de recherche sur le cancer de l'Université LavalQuébecCanada
| |
Collapse
|
3
|
Hotaki LT, Shrestha A, Bennett MP, Valdes IL, Lee SH, Wang Y, Spillman D, MacAulay T, Hunt M, Gervais J, Mafi M, Panetta V, Looi YH, Shum M, Atiek E, Meincke R, Rohr UP, Ainbinder D, Boehm-Cagan A, Luxenburg O, Cerqueira MR, Mouawad LS, Thees MFRES, Prasad K, de Claro RA. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners. Ther Innov Regul Sci 2023; 57:875-885. [PMID: 37072651 DOI: 10.1007/s43441-023-00522-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Accepted: 03/31/2023] [Indexed: 04/20/2023]
Abstract
Project Orbis was initiated in May 2019 by the Oncology Center of Excellence to facilitate faster patient access to innovative cancer therapies by providing a framework for concurrent submissions and review of oncology products among international partners. Since its inception, Australia's Therapeutic Goods Administration (TGA), Canada's Health Canada (HC), Singapore's Health Sciences Authority (HSA), Switzerland's Swissmedic (SMC), Brazil's National Health Surveillance Agency (ANVISA), United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA), and most recently Israel's Ministry of Health (IMoH) Medical Technologies, Health Information, Innovation and Research (MTIIR) Directorate, have joined Project Orbis. While each country has its own expedited review pathways to bring promising therapies to patients, there are some similarities and differences in pathways and timelines. FDA's fast-track designation and MHRA's marketing authorization under exceptional circumstances (MAEC) allow non-clinical and limited clinical evidence to support approval under these programs. HC's Extraordinary Use New Drug (EUND) pathway allows granting exceptional use authorization with limited clinical evidence. ANVISA, HSA, MTIIR, and TGA do not have standard pathways that allow non-clinical evidence and limited clinical evidence. While there is no definite regulatory pathway for HSA, the current framework for approval does allow flexibility in the type of data (non-clinical or clinical) required to demonstrate the benefit-risk profile of a product. HSA may register a product if the agency is satisfied that the overall benefit outweighs the risk. All Project Orbis Partner (POP) countries have similar programs to the FDA accelerated approval program except ANVISA. Although HSA and MTIIR do not have defined pathways for accelerated approval programs, there are opportunities to request accelerated approval per these agencies. All POP countries have pathways like the FDA priority review except MHRA. Priority review timelines for new drugs range from 120 to 264 calendar days (cd). Standard review timelines for new drugs range from 180 to 365 cd.
Collapse
Affiliation(s)
- Lauren T Hotaki
- U.S. Food and Drug Administration, Oncology Center for Excellence, Silver Spring, MD, USA.
| | - Anu Shrestha
- The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Monica P Bennett
- University of Florida College of Pharmacy, Jacksonville and Gainesville, FL, USA
| | - Ivelisse L Valdes
- University of Florida College of Pharmacy, Jacksonville and Gainesville, FL, USA
| | - Sso H Lee
- Division of Regulatory Operations for Oncologic Diseases, Silver Spring, MD, USA
- University of Georgia College of Pharmacy, Athens, GA, USA
| | - Yinghua Wang
- U.S. Food and Drug Administration, Oncology Center for Excellence, Silver Spring, MD, USA
| | - Dianne Spillman
- U.S. Food and Drug Administration, Oncology Center for Excellence, Silver Spring, MD, USA
| | - Tina MacAulay
- U.S. Food and Drug Administration, Oncology Center for Excellence, Silver Spring, MD, USA
| | | | | | | | | | | | - Michael Shum
- Therapeutic Goods Administration, Canberra, ACT, Australia
| | - Eiman Atiek
- Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland
| | - Ricarda Meincke
- Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland
| | - Ulrich-Peter Rohr
- Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland
| | - Denize Ainbinder
- The Medical Technologies, Health Information, Innovation and Research Directorate, Ministry of Health, Jerusalem, Israel
| | - Anat Boehm-Cagan
- The Medical Technologies, Health Information, Innovation and Research Directorate, Ministry of Health, Jerusalem, Israel
| | - Osnat Luxenburg
- The Medical Technologies, Health Information, Innovation and Research Directorate, Ministry of Health, Jerusalem, Israel
| | | | | | | | - Krishna Prasad
- Hon Consultant, DD Innovative Medicines, Medicines and Healthcare Products Regulatory Agency, St Thomas's Hospital, London, UK
| | - R Angelo de Claro
- U.S. Food and Drug Administration, Oncology Center for Excellence, Silver Spring, MD, USA
- Office of Oncologic Diseases, Silver Spring, MD, USA
| |
Collapse
|
4
|
Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, Harvey M, Neveu B, Loehr J, Bergeron A, Fradet Y, Lacombe L, Riopel J, Latulippe É, Atallah C, Shum M, Lambert JP, Pouliot F, Pelletier M, Audet-Walsh É. Abstract 3700: Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle in prostate cancer. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-3700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: The androgen receptor (AR) is an established orchestrator of cell metabolism in prostate cancer (PCa), notably by inducing an oxidative mitochondrial program. Intriguingly, AR regulates cytoplasmic isocitrate dehydrogenase 1 (IDH1) but not its mitochondrial counterparts IDH2 and IDH3. Here, we aimed to understand the functional role of IDH1 in PCa.
Methods: Mouse models, in vitro human PCa cell lines, and human prostate organoids were used to study the expression and activity of IDH enzymes in the normal prostate and PCa. Genetic and pharmacological inhibition of IDH1 was then combined with extracellular flux analysis and gas chromatography-mass spectrometry for metabolomic analyses and cancer cell proliferation in vitro and in vivo.
Results: In PCa cells, more than 90% of the total IDH activity is mediated through IDH1 rather than its mitochondrial counterparts. This profile seems to originate from the specialized prostate metabolic program, as observed using mouse prostate and human patient-derived organoids. Pharmacological and genetic inhibition of IDH1 impaired mitochondrial respiration, suggesting that this cytoplasmic enzyme contributes to the mitochondrial tricarboxylic acid cycle (TCA) in PCa. Mass spectrometry-based metabolomics confirmed this hypothesis, showing that inhibition of IDH1 impairs carbon flux into the TCA cycle. Consequently, inhibition of IDH1 decreased PCa cell proliferation in vitro and in vivo.
Conclusions: These results demonstrate that PCa cells have a hybrid cytoplasmic-mitochondrial TCA cycle that depends on IDH1. This metabolic enzyme represents a metabolic vulnerability of PCa cells and a potential new therapeutic target.
Citation Format: Kevin Gonthier, Cindy Weidmann, Line Berthiaume, Cynthia Jobin, Aurélie Lacouture, Camille Lafront, Mario Harvey, Bertrand Neveu, Jérémy Loehr, Alain Bergeron, Yves Fradet, Louis Lacombe, Julie Riopel, Éva Latulippe, Chantal Atallah, Michael Shum, Jean-Philippe Lambert, Frédéric Pouliot, Martin Pelletier, Étienne Audet-Walsh. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle in prostate cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3700.
Collapse
Affiliation(s)
| | - Cindy Weidmann
- 2CRCHU de Québec-Université Laval, Québec, Quebec, Canada
| | | | | | | | | | - Mario Harvey
- 2CRCHU de Québec-Université Laval, Québec, Quebec, Canada
| | | | - Jérémy Loehr
- 2CRCHU de Québec-Université Laval, Québec, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Briottet M, Shum M, London M, Baillif V, Escabasse V, Dubourdeau M, Louis B, Urbach V. ePS6.04 Specialised pro-resolving mediators’ biosynthesis by cystic fibrosis airway epithelial cells and their impact on mucociliary clearance. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00331-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Shum M, Segawa M, Gharakhanian R, Viñuela A, Wortham M, Baghdasarian S, Wolf DM, Sereda SB, Nocito L, Stiles L, Zhou Z, Gutierrez V, Sander M, Shirihai OS, Liesa M. Deletion of ABCB10 in beta-cells protects from high-fat diet induced insulin resistance. Mol Metab 2022; 55:101403. [PMID: 34823065 PMCID: PMC8689243 DOI: 10.1016/j.molmet.2021.101403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Revised: 11/18/2021] [Accepted: 11/19/2021] [Indexed: 11/09/2022] Open
Abstract
OBJECTIVE The contribution of beta-cell dysfunction to type 2 diabetes (T2D) is not restricted to insulinopenia in the late stages of the disease. Elevated fasting insulinemia in normoglycemic humans is a major factor predicting the onset of insulin resistance and T2D, demonstrating an early alteration of beta-cell function in T2D. Moreover, an early and chronic increase in fasting insulinemia contributes to insulin resistance in high-fat diet (HFD)-fed mice. However, whether there are genetic factors that promote beta-cell-initiated insulin resistance remains undefined. Human variants of the mitochondrial transporter ABCB10, which regulates redox by increasing bilirubin synthesis, have been associated with an elevated risk of T2D. The effects of T2D ABCB10 variants on ABCB10 expression and the actions of ABCB10 in beta-cells are unknown. METHODS The expression of beta-cell ABCB10 was analyzed in published transcriptome datasets from human beta-cells carrying the T2D-risk ABCB10 variant. Insulin sensitivity, beta-cell proliferation, and secretory function were measured in beta-cell-specific ABCB10 KO mice (Ins1Cre-Abcb10flox/flox). The short-term role of beta-cell ABCB10 activity on glucose-stimulated insulin secretion (GSIS) was determined in isolated islets. RESULTS Carrying the T2Drisk allele G of ABCB10 rs348330 variant was associated with increased ABCB10 expression in human beta-cells. Constitutive deletion of Abcb10 in beta-cells protected mice from hyperinsulinemia and insulin resistance by limiting HFD-induced beta-cell expansion. An early limitation in GSIS and H2O2-mediated signaling caused by elevated ABCB10 activity can initiate an over-compensatory expansion of beta-cell mass in response to HFD. Accordingly, increasing ABCB10 expression was sufficient to limit GSIS capacity. In health, ABCB10 protein was decreased during islet maturation, with maturation restricting beta-cell proliferation and elevating GSIS. Finally, ex-vivo and short-term deletion of ABCB10 in islets isolated from HFD-fed mice increased H2O2 and GSIS, which was reversed by bilirubin treatments. CONCLUSIONS Beta-cell ABCB10 is required for HFD to induce insulin resistance in mice by amplifying beta-cell mass expansion to maladaptive levels that cause fasting hyperinsulinemia.
Collapse
Affiliation(s)
- Michael Shum
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA; Department of Molecular Medicine, Faculty of Medicine, Universite Laval, Quebec City G1V 0A6, Canada.
| | - Mayuko Segawa
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Raffi Gharakhanian
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Ana Viñuela
- Bioscience Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom
| | - Matthew Wortham
- Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California, San Diego, La Jolla, CA 92093, USA
| | - Siyouneh Baghdasarian
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Dane M Wolf
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA; Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA, 02118, USA
| | - Samuel B Sereda
- Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA, 02118, USA
| | - Laura Nocito
- Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA, 02118, USA
| | - Linsey Stiles
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Zhiqiang Zhou
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Vincent Gutierrez
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA; Molecular and Cellular Integrative Physiology, UCLA, 612 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Maike Sander
- Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California, San Diego, La Jolla, CA 92093, USA
| | - Orian S Shirihai
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA; Molecular and Cellular Integrative Physiology, UCLA, 612 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Marc Liesa
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA; Molecular and Cellular Integrative Physiology, UCLA, 612 Charles E. Young Dr., Los Angeles, CA 90095, USA; Molecular Biology Institute at UCLA, 611 Charles E. Young Dr., Los Angeles, CA 90095, USA.
| |
Collapse
|
7
|
Shum M, Zhou Z, Liesa M. Determining Basal Energy Expenditure and the Capacity of Thermogenic Adipocytes to Expend Energy in Obese Mice. J Vis Exp 2021. [PMID: 34842229 DOI: 10.3791/63066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Energy expenditure measurements are necessary to understand how changes in metabolism can lead to obesity. Basal energy expenditure can be determined in mice by measuring whole-body oxygen consumption, CO2 production, and physical activity using metabolic cages. Thermogenic brown/beige adipocytes (BA) contribute significantly to rodent energy expenditure, particularly at low ambient temperatures. Here, measurements of basal energy expenditure and total BA capacity to expend energy in obese mice are described in two detailed protocols: the first explaining how to set up the assay to measure basal energy expenditure using analysis of covariance (ANCOVA), a necessary analysis given that energy expenditure co-varies with body mass. The second protocol describes how to measure BA energy expenditure capacity in vivo in mice. This procedure involves anesthesia, needed to limit expenditure caused by physical activity, followed by the injection of beta3-adrenergic agonist, CL-316,243, which activates energy expenditure in BA. These two protocols and their limitations are described in sufficient detail to allow a successful first experiment.
Collapse
Affiliation(s)
- Michael Shum
- Department of Molecular Medicine, Faculty of Medicine, Universite Laval;
| | - Zhiqiang Zhou
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA
| | - Marc Liesa
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA; Molecular Biology Institute at UCLA;
| |
Collapse
|
8
|
Chella Krishnan K, Vergnes L, Acín-Pérez R, Stiles L, Shum M, Ma L, Mouisel E, Pan C, Moore TM, Péterfy M, Romanoski CE, Reue K, Björkegren JLM, Laakso M, Liesa M, Lusis AJ. Sex-specific genetic regulation of adipose mitochondria and metabolic syndrome by Ndufv2. Nat Metab 2021; 3:1552-1568. [PMID: 34697471 PMCID: PMC8909918 DOI: 10.1038/s42255-021-00481-w] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 09/17/2021] [Indexed: 12/28/2022]
Abstract
We have previously suggested a central role for mitochondria in the observed sex differences in metabolic traits. However, the mechanisms by which sex differences affect adipose mitochondrial function and metabolic syndrome are unclear. Here we show that in both mice and humans, adipose mitochondrial functions are elevated in females and are strongly associated with adiposity, insulin resistance and plasma lipids. Using a panel of diverse inbred strains of mice, we identify a genetic locus on mouse chromosome 17 that controls mitochondrial mass and function in adipose tissue in a sex- and tissue-specific manner. This locus contains Ndufv2 and regulates the expression of at least 89 mitochondrial genes in females, including oxidative phosphorylation genes and those related to mitochondrial DNA content. Overexpression studies indicate that Ndufv2 mediates these effects by regulating supercomplex assembly and elevating mitochondrial reactive oxygen species production, which generates a signal that increases mitochondrial biogenesis.
Collapse
Affiliation(s)
- Karthickeyan Chella Krishnan
- Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
- Department of Medicine/Division of Cardiology, University of California, Los Angeles, CA, USA.
| | - Laurent Vergnes
- Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA
| | - Rebeca Acín-Pérez
- Department of Medicine/Division of Endocrinology, University of California, Los Angeles, Los Angeles, CA, USA
| | - Linsey Stiles
- Department of Medicine/Division of Endocrinology, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA
| | - Michael Shum
- Department of Medicine/Division of Endocrinology, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Molecular Medicine, Faculty of Medicine, Universite Laval, Quebec City, Quebec, Canada
| | - Lijiang Ma
- Department of Genetics and Genomic Sciences, The Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Etienne Mouisel
- INSERM, UMR1297, Institute of Metabolic and Cardiovascular Diseases, University of Toulouse, Paul Sabatier University, Toulouse, France
| | - Calvin Pan
- Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA
| | - Timothy M Moore
- Department of Medicine/Division of Cardiology, University of California, Los Angeles, CA, USA
| | - Miklós Péterfy
- Department of Medicine/Division of Cardiology, University of California, Los Angeles, CA, USA
- College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA
| | - Casey E Romanoski
- Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA
| | - Karen Reue
- Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA
| | - Johan L M Björkegren
- Department of Genetics and Genomic Sciences, The Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden
| | - Markku Laakso
- Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
| | - Marc Liesa
- Department of Medicine/Division of Endocrinology, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA
| | - Aldons J Lusis
- Department of Medicine/Division of Cardiology, University of California, Los Angeles, CA, USA.
- Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
- Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
| |
Collapse
|
9
|
Shum M, Shintre CA, Althoff T, Gutierrez V, Segawa M, Saxberg AD, Martinez M, Adamson R, Young MR, Faust B, Gharakhanian R, Su S, Chella Krishnan K, Mahdaviani K, Veliova M, Wolf DM, Ngo J, Nocito L, Stiles L, Abramson J, Lusis AJ, Hevener AL, Zoghbi ME, Carpenter EP, Liesa M. ABCB10 exports mitochondrial biliverdin, driving metabolic maladaptation in obesity. Sci Transl Med 2021; 13:13/594/eabd1869. [PMID: 34011630 DOI: 10.1126/scitranslmed.abd1869] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 01/25/2021] [Accepted: 04/20/2021] [Indexed: 12/12/2022]
Abstract
Although the role of hydrophilic antioxidants in the development of hepatic insulin resistance and nonalcoholic fatty liver disease has been well studied, the role of lipophilic antioxidants remains poorly characterized. A known lipophilic hydrogen peroxide scavenger is bilirubin, which can be oxidized to biliverdin and then reduced back to bilirubin by cytosolic biliverdin reductase. Oxidation of bilirubin to biliverdin inside mitochondria must be followed by the export of biliverdin to the cytosol, where biliverdin is reduced back to bilirubin. Thus, the putative mitochondrial exporter of biliverdin is expected to be a major determinant of bilirubin regeneration and intracellular hydrogen peroxide scavenging. Here, we identified ABCB10 as a mitochondrial biliverdin exporter. ABCB10 reconstituted into liposomes transported biliverdin, and ABCB10 deletion caused accumulation of biliverdin inside mitochondria. Obesity with insulin resistance up-regulated hepatic ABCB10 expression in mice and elevated cytosolic and mitochondrial bilirubin content in an ABCB10-dependent manner. Revealing a maladaptive role of ABCB10-driven bilirubin synthesis, hepatic ABCB10 deletion protected diet-induced obese mice from steatosis and hyperglycemia, improving insulin-mediated suppression of glucose production and decreasing lipogenic SREBP-1c expression. Protection was concurrent with enhanced mitochondrial function and increased inactivation of PTP1B, a phosphatase disrupting insulin signaling and elevating SREBP-1c expression. Restoration of cellular bilirubin content in ABCB10 KO hepatocytes reversed the improvements in mitochondrial function and PTP1B inactivation, demonstrating that bilirubin was the maladaptive effector linked to ABCB10 function. Thus, we identified a fundamental transport process that amplifies intracellular bilirubin redox actions, which can exacerbate insulin resistance and steatosis in obesity.
Collapse
Affiliation(s)
- Michael Shum
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA
| | - Chitra A Shintre
- Center for Medicines Discovery, University of Oxford, Oxfordshire OX3 7DQ, UK
| | - Thorsten Althoff
- Department of Physiology, University of California, Los Angeles, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Vincent Gutierrez
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA
| | - Mayuko Segawa
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA
| | - Alexandra D Saxberg
- Department of Molecular Cell Biology, School of Natural Sciences, University of California, Merced, 5200 North Lake Rd., Merced, CA 95343, USA
| | - Melissa Martinez
- Department of Molecular Cell Biology, School of Natural Sciences, University of California, Merced, 5200 North Lake Rd., Merced, CA 95343, USA
| | - Roslin Adamson
- Center for Medicines Discovery, University of Oxford, Oxfordshire OX3 7DQ, UK
| | - Margaret R Young
- Center for Medicines Discovery, University of Oxford, Oxfordshire OX3 7DQ, UK
| | - Belinda Faust
- Center for Medicines Discovery, University of Oxford, Oxfordshire OX3 7DQ, UK
| | - Raffi Gharakhanian
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA
| | - Shi Su
- Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA 02118, USA
| | - Karthickeyan Chella Krishnan
- Department of Human Genetics, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0575, USA
| | - Kiana Mahdaviani
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA 02118, USA
| | - Michaela Veliova
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Dane M Wolf
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA 02118, USA
| | - Jennifer Ngo
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA.,Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Laura Nocito
- Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA 02118, USA
| | - Linsey Stiles
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Jeff Abramson
- Department of Physiology, University of California, Los Angeles, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Aldons J Lusis
- Department of Human Genetics, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Andrea L Hevener
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA
| | - Maria E Zoghbi
- Department of Molecular Cell Biology, School of Natural Sciences, University of California, Merced, 5200 North Lake Rd., Merced, CA 95343, USA
| | | | - Marc Liesa
- Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA. .,Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.,Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA
| |
Collapse
|
10
|
Ngo J, Benador IY, Brownstein AJ, Vergnes L, Veliova M, Shum M, Acín-Pérez R, Reue K, Shirihai OS, Liesa M. Isolation and functional analysis of peridroplet mitochondria from murine brown adipose tissue. STAR Protoc 2021; 2:100243. [PMID: 33458705 PMCID: PMC7797917 DOI: 10.1016/j.xpro.2020.100243] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Mitochondria play a central role in lipid metabolism and can bind to lipid droplets. However, the role and functional specialization of the population of peridroplet mitochondria (PDMs) remain unclear, as methods to isolate functional PDMs were not developed until recently. Here, we describe an approach to isolate intact PDMs from murine brown adipose tissue based on their adherence to lipid droplets. PDMs isolated using our approach can be used to study their specialized function by respirometry. For complete information on the use and execution of this protocol, please refer to Benador et al. (2018). Isolation of peridroplet mitochondria (PDMs) from brown adipose tissue is described The function of murine PDMs is analyzed using 96-well format respirometry QC steps of PDM isolation by imaging and protein biochemistry are defined
Collapse
Affiliation(s)
- Jennifer Ngo
- Department of Medicine, Division of Endocrinology and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Department of Chemistry and Biochemistry at UCLA, Los Angeles, CA 90095, USA.,Metabolism Theme, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Ilan Y Benador
- Department of Medicine, Division of Endocrinology and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Alexandra J Brownstein
- Department of Medicine, Division of Endocrinology and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Metabolism Theme, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Laurent Vergnes
- Metabolism Theme, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
| | - Michaela Veliova
- Department of Medicine, Division of Endocrinology and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Metabolism Theme, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Michael Shum
- Department of Medicine, Division of Endocrinology and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Metabolism Theme, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Rebeca Acín-Pérez
- Department of Medicine, Division of Endocrinology and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Metabolism Theme, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Karen Reue
- Metabolism Theme, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA.,Molecular Biology Institute at UCLA, Los Angeles, CA 90095, USA
| | - Orian S Shirihai
- Department of Medicine, Division of Endocrinology and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Metabolism Theme, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Marc Liesa
- Department of Medicine, Division of Endocrinology and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Metabolism Theme, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.,Molecular Biology Institute at UCLA, Los Angeles, CA 90095, USA
| |
Collapse
|
11
|
Spira A, Riely G, Lawler W, Shum M, Socinski M, Yanagihara R, Roshan S, Kheoh T, Christensen J, Chao R, Janne P, Garassino M. P90.03 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1286] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Shum M, London M, Briottet M, Remus N, Escabasse V, Dubourdeau M, Urbach V. WS05.4 The role of airway epithelial cells in the abnormal biosynthesis of specialised pro-resolving lipid mediators in cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)00942-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Zhang Z, Reis FMCV, He Y, Park JW, DiVittorio JR, Sivakumar N, van Veen JE, Maesta-Pereira S, Shum M, Nichols I, Massa MG, Anderson S, Paul K, Liesa M, Ajijola OA, Xu Y, Adhikari A, Correa SM. Estrogen-sensitive medial preoptic area neurons coordinate torpor in mice. Nat Commun 2020; 11:6378. [PMID: 33311503 PMCID: PMC7732979 DOI: 10.1038/s41467-020-20050-1] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Accepted: 11/12/2020] [Indexed: 12/15/2022] Open
Abstract
Homeotherms maintain a stable internal body temperature despite changing environments. During energy deficiency, some species can cease to defend their body temperature and enter a hypothermic and hypometabolic state known as torpor. Recent advances have revealed the medial preoptic area (MPA) as a key site for the regulation of torpor in mice. The MPA is estrogen-sensitive and estrogens also have potent effects on both temperature and metabolism. Here, we demonstrate that estrogen-sensitive neurons in the MPA can coordinate hypothermia and hypometabolism in mice. Selectively activating estrogen-sensitive MPA neurons was sufficient to drive a coordinated depression of metabolic rate and body temperature similar to torpor, as measured by body temperature, physical activity, indirect calorimetry, heart rate, and brain activity. Inducing torpor with a prolonged fast revealed larger and more variable calcium transients from estrogen-sensitive MPA neurons during bouts of hypothermia. Finally, whereas selective ablation of estrogen-sensitive MPA neurons demonstrated that these neurons are required for the full expression of fasting-induced torpor in both female and male mice, their effects on thermoregulation and torpor bout initiation exhibit differences across sex. Together, these findings suggest a role for estrogen-sensitive MPA neurons in directing the thermoregulatory and metabolic responses to energy deficiency.
Collapse
Affiliation(s)
- Zhi Zhang
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA
- Brain Research Institute, University of California Los Angeles, Los Angeles, CA, USA
| | - Fernando M C V Reis
- Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA
| | - Yanlin He
- USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA
| | - Jae W Park
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA
| | - Johnathon R DiVittorio
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA
| | - Nilla Sivakumar
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA
| | - J Edward van Veen
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA
- Brain Research Institute, University of California Los Angeles, Los Angeles, CA, USA
| | - Sandra Maesta-Pereira
- Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA
| | - Michael Shum
- Division of Endocrinology, Department of Medicine, David Geffen School of Medicine, Los Angeles, CA, USA
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Los Angeles, CA, USA
| | - India Nichols
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA
| | - Megan G Massa
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA
- Brain Research Institute, University of California Los Angeles, Los Angeles, CA, USA
| | - Shawn Anderson
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA
| | - Ketema Paul
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA
| | - Marc Liesa
- Division of Endocrinology, Department of Medicine, David Geffen School of Medicine, Los Angeles, CA, USA
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Los Angeles, CA, USA
| | - Olujimi A Ajijola
- UCLA Cardiac Arrhythmia Center, Department of Medicine, David Geffen School of Medicine, Los Angeles, CA, USA
| | - Yong Xu
- USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Avishek Adhikari
- Brain Research Institute, University of California Los Angeles, Los Angeles, CA, USA
- Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA
| | - Stephanie M Correa
- Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA.
- Brain Research Institute, University of California Los Angeles, Los Angeles, CA, USA.
| |
Collapse
|
14
|
de Claro RA, Spillman D, Hotaki LT, Shum M, Mouawad LS, Santos GML, Robinson K, Hunt M, Healy C, Chan A, Looi YH, Rodrigues C, Rohr UP, Walther C, Pazdur R. Project Orbis: Global Collaborative Review Program. Clin Cancer Res 2020; 26:6412-6416. [PMID: 33037016 DOI: 10.1158/1078-0432.ccr-20-3292] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 09/16/2020] [Accepted: 10/07/2020] [Indexed: 11/16/2022]
Abstract
In 2019, the FDA Oncology Center of Excellence launched Project Orbis, a global collaborative review program to facilitate faster patient access to innovative cancer therapies across multiple countries. Project Orbis aims for concurrent submission, review, and regulatory action for high-impact clinically significant marketing applications among the participating partner countries. Current Project Orbis partners (POP) include the regulatory health authorities (RHA) of Australia, Brazil, Canada, Singapore, and Switzerland. Project Orbis leverages the existing scientific and regulatory partnerships between the various RHA under mutual confidentiality agreements. While FDA serves as the primary coordinator for application selection and review, each country remains fully independent on their final regulatory decision. In the first year of Project Orbis (June 2019 to June 2020), a total of 60 oncology marketing applications were received, representing 16 unique projects, and resulting in 38 approvals. New molecular entities, also known as new active substances, comprised 28% of the received marketing applications. The median time gap between FDA and Orbis submission dates was 0.6 months with a range of -0.8 to 9.0 months. Across the program, the median time-to-approval was similar between FDA (4.2 months, range 0.9-6.9, N = 18) and the POP (4.4 months, range 1.7-6.8, N = 20). Participating countries have signified a strong commitment for continuation and growth of the program. Project Orbis expansion considerations include the addition of more countries and management of more complex applications.
Collapse
Affiliation(s)
- R Angelo de Claro
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland. .,Office of Oncologic Diseases, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Dianne Spillman
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Lauren Tesh Hotaki
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland
| | | | | | | | | | | | | | | | | | | | | | - Chantal Walther
- Swiss Agency for Therapeutic Products (Swissmedic), Switzerland
| | - Richard Pazdur
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.,Office of Oncologic Diseases, U.S. Food and Drug Administration, Silver Spring, Maryland
| |
Collapse
|
15
|
van Veen JE, Kammel LG, Bunda PC, Shum M, Reid MS, Massa MG, Arneson D, Park JW, Zhang Z, Joseph AM, Hrncir H, Liesa M, Arnold AP, Yang X, Correa SM. Hypothalamic estrogen receptor alpha establishes a sexually dimorphic regulatory node of energy expenditure. Nat Metab 2020; 2:351-363. [PMID: 32377634 PMCID: PMC7202561 DOI: 10.1038/s42255-020-0189-6] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 03/12/2020] [Indexed: 12/26/2022]
Abstract
Estrogen receptor a (ERa) signaling in the ventromedial hypothalamus (VMH) contributes to energy homeostasis by modulating physical activity and thermogenesis. However, the precise neuronal populations involved remain undefined. Here, we describe six neuronal populations in the mouse VMH by using single-cell RNA transcriptomics and in situ hybridization. ERa is enriched in populations showing sex biased expression of reprimo (Rprm), tachykinin 1 (Tac1), and prodynorphin (Pdyn). Female biased expression of Tac1 and Rprm is patterned by ERa-dependent repression during male development, whereas male biased expression of Pdyn is maintained by circulating testicular hormone in adulthood. Chemogenetic activation of ERa positive VMH neurons stimulates heat generation and movement in both sexes. However, silencing Rprm gene function increases core temperature selectively in females and ectopic Rprm expression in males is associated with reduced core temperature. Together these findings reveal a role for Rprm in temperature regulation and ERa in the masculinization of neuron populations that underlie energy expenditure.
Collapse
Affiliation(s)
- J Edward van Veen
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
- Laboratory of Neuroendocrinology of the Brain Research Institute, University of California, Los Angeles, CA, USA
- authors contributed equally
| | - Laura G Kammel
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
- Laboratory of Neuroendocrinology of the Brain Research Institute, University of California, Los Angeles, CA, USA
- Molecular, Cellular, and Integrative Physiology Graduate Program, University of California, Los Angeles, CA, USA
- authors contributed equally
| | - Patricia C Bunda
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
| | - Michael Shum
- Division of Endocrinology, Department of Medicine, and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- Molecular Biology Institute, University of California, Los Angeles, CA, USA
| | - Michelle S Reid
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
| | - Megan G Massa
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
- Laboratory of Neuroendocrinology of the Brain Research Institute, University of California, Los Angeles, CA, USA
- Neuroscience Interdepartmental Doctoral Program, University of California, Los Angeles, CA, USA
| | - Douglas Arneson
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
| | - Jae W Park
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
| | - Zhi Zhang
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
- Laboratory of Neuroendocrinology of the Brain Research Institute, University of California, Los Angeles, CA, USA
| | - Alexia M Joseph
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
| | - Haley Hrncir
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
| | - Marc Liesa
- Division of Endocrinology, Department of Medicine, and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- Molecular Biology Institute, University of California, Los Angeles, CA, USA
| | - Arthur P Arnold
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
- Laboratory of Neuroendocrinology of the Brain Research Institute, University of California, Los Angeles, CA, USA
| | - Xia Yang
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
| | - Stephanie M Correa
- Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA
- Laboratory of Neuroendocrinology of the Brain Research Institute, University of California, Los Angeles, CA, USA
| |
Collapse
|
16
|
Ward J, Shum M, Bertino E, Lin V, Kuruvadi V, Heineman T. Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
17
|
Shum M, Houde VP, Bellemare V, Junges Moreira R, Bellmann K, St-Pierre P, Viollet B, Foretz M, Marette A. Inhibition of mitochondrial complex 1 by the S6K1 inhibitor PF-4708671 partly contributes to its glucose metabolic effects in muscle and liver cells. J Biol Chem 2019; 294:12250-12260. [PMID: 31243102 DOI: 10.1074/jbc.ra119.008488] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Revised: 06/18/2019] [Indexed: 11/06/2022] Open
Abstract
mTOR complex 1 (mTORC1) and p70 S6 kinase (S6K1) are both involved in the development of obesity-linked insulin resistance. Recently, we showed that the S6K1 inhibitor PF-4708671 (PF) increases insulin sensitivity. However, we also reported that PF can increase glucose metabolism even in the absence of insulin in muscle and hepatic cells. Here we further explored the potential mechanisms by which PF increases glucose metabolism in muscle and liver cells independent of insulin. Time course experiments revealed that PF induces AMP-activated protein kinase (AMPK) activation before inhibiting S6K1. However, PF-induced glucose uptake was not prevented in primary muscle cells from AMPK α1/2 double KO (dKO) mice. Moreover, PF-mediated suppression of hepatic glucose production was maintained in hepatocytes derived from AMPK α1/2-dKO mice. Remarkably, PF could still reduce glucose production and activate AMPK in hepatocytes from S6K1/2 dKO mice. Mechanistically, bioenergetics experiments revealed that PF reduces mitochondrial complex I activity in both muscle and hepatic cells. The stimulatory effect of PF on glucose uptake was partially reduced by expression of the Saccharomyces cerevisiae NADH:ubiquinone oxidoreductase in L6 cells. These results indicate that PF-mediated S6K1 inhibition is not required for its effect on insulin-independent glucose metabolism and AMPK activation. We conclude that, although PF rapidly activates AMPK, its ability to acutely increase glucose uptake and suppress glucose production does not require AMPK activation. Unexpectedly, PF rapidly inhibits mitochondrial complex I activity, a mechanism that partially underlies PF's effect on glucose metabolism.
Collapse
Affiliation(s)
- Michael Shum
- Department of Medicine, Quebec Heart and Lung Institute, Université Laval, Québec G1V 4G5, Canada
| | - Vanessa P Houde
- Department of Medicine, Quebec Heart and Lung Institute, Université Laval, Québec G1V 4G5, Canada
| | - Vicky Bellemare
- Department of Medicine, Quebec Heart and Lung Institute, Université Laval, Québec G1V 4G5, Canada
| | - Rafael Junges Moreira
- Department of Medicine, Quebec Heart and Lung Institute, Université Laval, Québec G1V 4G5, Canada
| | - Kerstin Bellmann
- Department of Medicine, Quebec Heart and Lung Institute, Université Laval, Québec G1V 4G5, Canada
| | - Philippe St-Pierre
- Department of Medicine, Quebec Heart and Lung Institute, Université Laval, Québec G1V 4G5, Canada
| | - Benoit Viollet
- INSERM, U1016, Institut Cochin, 75014 Paris, France; CNRS, UMR8104, 75014 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 75014 Paris, France
| | - Marc Foretz
- INSERM, U1016, Institut Cochin, 75014 Paris, France; CNRS, UMR8104, 75014 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 75014 Paris, France
| | - André Marette
- Department of Medicine, Quebec Heart and Lung Institute, Université Laval, Québec G1V 4G5, Canada.
| |
Collapse
|
18
|
Shum M, Assikis V, Savulsky C, Zhu W, Iyer P, Xing D, Berman C, Lokker N, Alvarez R. Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Kjøbsted R, Hingst JR, Fentz J, Foretz M, Sanz MN, Pehmøller C, Shum M, Marette A, Mounier R, Treebak JT, Wojtaszewski JFP, Viollet B, Lantier L. AMPK in skeletal muscle function and metabolism. FASEB J 2018; 32:1741-1777. [PMID: 29242278 PMCID: PMC5945561 DOI: 10.1096/fj.201700442r] [Citation(s) in RCA: 249] [Impact Index Per Article: 41.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Skeletal muscle possesses a remarkable ability to adapt to various physiologic conditions. AMPK is a sensor of intracellular energy status that maintains energy stores by fine-tuning anabolic and catabolic pathways. AMPK’s role as an energy sensor is particularly critical in tissues displaying highly changeable energy turnover. Due to the drastic changes in energy demand that occur between the resting and exercising state, skeletal muscle is one such tissue. Here, we review the complex regulation of AMPK in skeletal muscle and its consequences on metabolism (e.g., substrate uptake, oxidation, and storage as well as mitochondrial function of skeletal muscle fibers). We focus on the role of AMPK in skeletal muscle during exercise and in exercise recovery. We also address adaptations to exercise training, including skeletal muscle plasticity, highlighting novel concepts and future perspectives that need to be investigated. Furthermore, we discuss the possible role of AMPK as a therapeutic target as well as different AMPK activators and their potential for future drug development.—Kjøbsted, R., Hingst, J. R., Fentz, J., Foretz, M., Sanz, M.-N., Pehmøller, C., Shum, M., Marette, A., Mounier, R., Treebak, J. T., Wojtaszewski, J. F. P., Viollet, B., Lantier, L. AMPK in skeletal muscle function and metabolism.
Collapse
Affiliation(s)
- Rasmus Kjøbsted
- Section of Molecular Physiology, Department of Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark
| | - Janne R Hingst
- Section of Molecular Physiology, Department of Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark
| | - Joachim Fentz
- Section of Molecular Physiology, Department of Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark
| | - Marc Foretz
- INSERM, Unité 1016, Institut Cochin, Paris, France.,Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 8104, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Maria-Nieves Sanz
- Department of Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, and.,Department of Biomedical Research, University of Bern, Bern, Switzerland
| | - Christian Pehmøller
- Internal Medicine Research Unit, Pfizer Global Research and Development, Cambridge, Massachusetts, USA
| | - Michael Shum
- Axe Cardiologie, Quebec Heart and Lung Research Institute, Laval University, Québec, Canada.,Institute for Nutrition and Functional Foods, Laval University, Québec, Canada
| | - André Marette
- Axe Cardiologie, Quebec Heart and Lung Research Institute, Laval University, Québec, Canada.,Institute for Nutrition and Functional Foods, Laval University, Québec, Canada
| | - Remi Mounier
- Institute NeuroMyoGène, Université Claude Bernard Lyon 1, INSERM Unité 1217, CNRS UMR, Villeurbanne, France
| | - Jonas T Treebak
- Section of Integrative Physiology, Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Jørgen F P Wojtaszewski
- Section of Molecular Physiology, Department of Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark
| | - Benoit Viollet
- INSERM, Unité 1016, Institut Cochin, Paris, France.,Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 8104, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Louise Lantier
- Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, USA.,Mouse Metabolic Phenotyping Center, Vanderbilt University, Nashville, Tennessee, USA
| |
Collapse
|
20
|
Bazhenova L, Mehra R, Nagy T, Cavanna L, Lee JS, Han JY, Kim H, Halmos B, Shum M, Schreeder M, Rybkin I, Badin F, Mena R, Jänne P, Christensen J, Tassell V, Chao R, Faltaos D, Kim DW. Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.93] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Shum M, Beck J, Meyerhardt J, Patel R, Kochenderfer M, Crocenzi T, Patchen M, Gargano M, Ma B, Lowe J, Iglesias J. Levels of endogenous anti-beta-glucan IgG antibodies (ABA) predict clinical outcomes for imprime PGG: Evidence from phase 3 PRIMUS study in patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Shum M, Bellmann K, St-Pierre P, Marette A. Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice. Diabetologia 2016; 59:592-603. [PMID: 26733005 DOI: 10.1007/s00125-015-3839-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Accepted: 11/13/2015] [Indexed: 01/08/2023]
Abstract
AIMS/HYPOTHESIS The mammalian target of rapamycin complex 1 (mTORC1)/p70 ribosomal S6 kinase (S6K)1 pathway is overactivated in obesity, leading to inhibition of phosphoinositide 3-kinase (PI3K)/Akt signalling and insulin resistance. However, chronic mTORC1 inhibition by rapamycin impairs glucose homeostasis because of robust induction of liver gluconeogenesis. Here, we compared the effect of rapamycin with that of the selective S6K1 inhibitor, PF-4708671, on glucose metabolism in vitro and in vivo. METHODS We used L6 myocytes and FAO hepatocytes to explore the effect of PF-4708671 on the regulation of glucose uptake, glucose production and insulin signalling. We also treated high-fat (HF)-fed obese mice for 7 days with PF-4708671 in comparison with rapamycin to assess glucose tolerance, insulin resistance and insulin signalling in vivo. RESULTS Chronic rapamycin treatment induced insulin resistance and impaired glucose metabolism in hepatic and muscle cells. Conversely, chronic S6K1 inhibition with PF-4708671 reduced glucose production in hepatocytes and enhanced glucose uptake in myocytes. Whereas rapamycin treatment inhibited Akt phosphorylation, PF-4708671 increased Akt phosphorylation in both cell lines. These opposite effects of the mTORC1 and S6K1 inhibitors were also observed in vivo. Indeed, while rapamycin treatment induced glucose intolerance and failed to improve Akt phosphorylation in liver and muscle of HF-fed mice, PF-4708671 treatment improved glucose tolerance and increased Akt phosphorylation in metabolic tissues of these obese mice. CONCLUSIONS/INTERPRETATION Chronic S6K1 inhibition by PF-4708671 improves glucose homeostasis in obese mice through enhanced Akt activation in liver and muscle. Our results suggest that specific S6K1 blockade is a valid pharmacological approach to improve glucose disposal in obese diabetic individuals.
Collapse
Affiliation(s)
- Michael Shum
- Department of Medicine, Quebec Heart and Lung Institute, Hôpital Laval, Pavillon Marguerite d'Youville, Room Y4308, 2705 Chemin Ste-Foy, Québec, Canada, G1V 4G5
| | - Kerstin Bellmann
- Department of Medicine, Quebec Heart and Lung Institute, Hôpital Laval, Pavillon Marguerite d'Youville, Room Y4308, 2705 Chemin Ste-Foy, Québec, Canada, G1V 4G5
| | - Philippe St-Pierre
- Department of Medicine, Quebec Heart and Lung Institute, Hôpital Laval, Pavillon Marguerite d'Youville, Room Y4308, 2705 Chemin Ste-Foy, Québec, Canada, G1V 4G5
| | - André Marette
- Department of Medicine, Quebec Heart and Lung Institute, Hôpital Laval, Pavillon Marguerite d'Youville, Room Y4308, 2705 Chemin Ste-Foy, Québec, Canada, G1V 4G5.
| |
Collapse
|
23
|
Noll C, Labbé SM, Pinard S, Shum M, Bilodeau L, Chouinard L, Phoenix S, Lecomte R, Carpentier AC, Gallo-Payet N. Postprandial fatty acid uptake and adipocyte remodeling in angiotensin type 2 receptor-deficient mice fed a high-fat/high-fructose diet. Adipocyte 2016; 5:43-52. [PMID: 27144096 DOI: 10.1080/21623945.2015.1115582] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Revised: 10/20/2015] [Accepted: 10/27/2015] [Indexed: 12/16/2022] Open
Abstract
The role of the angiotensin type-2 receptor in adipose physiology remains controversial. The aim of the present study was to demonstrate whether genetic angiotensin type-2 receptor-deficiency prevents or worsens metabolic and adipose tissue morphometric changes observed following a 6-week high-fat/high-fructose diet with injection of a small dose of streptozotocin. We compared tissue uptake of nonesterified fatty acid and dietary fatty acid in wild-type and angiotensin type-2 receptor-deficient mice by using the radiotracer 14(R,S)-[(1) (8)F]-fluoro-6-thia-heptadecanoic acid in mice fed a standard or high-fat diet. Postprandial fatty acid uptake in the heart, liver, skeletal muscle, kidney and adipose tissue was increased in wild-type mice after a high-fat diet and in angiotensin type-2 receptor-deficient mice on both standard and high-fat diets. Compared to the wild-type mice, angiotensin type-2 receptor-deficient mice had a lower body weight, an increase in fasting blood glucose and a decrease in plasma insulin and leptin levels. Mice fed a high-fat diet exhibited increased adipocyte size that was prevented by angiotensin type-2 receptor-deficiency. Angiotensin type-2 receptor-deficiency abolished the early hypertrophic adipocyte remodeling induced by a high-fat diet. The small size of adipocytes in the angiotensin type-2 receptor-deficient mice reflects their inability to store lipids and explains the increase in fatty acid uptake in non-adipose tissues. In conclusion, a genetic deletion of the angiotensin type-2 receptor is associated with metabolic dysfunction of white adipose depots, and indicates that adipocyte remodeling occurs before the onset of insulin resistance in the high-fat fed mouse model.
Collapse
|
24
|
Smadja-Lamère N, Shum M, Déléris P, Roux PP, Abe JI, Marette A. Insulin activates RSK (p90 ribosomal S6 kinase) to trigger a new negative feedback loop that regulates insulin signaling for glucose metabolism. J Biol Chem 2013; 288:31165-76. [PMID: 24036112 DOI: 10.1074/jbc.m113.474148] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We previously demonstrated that the mTORC1/S6K1 pathway is activated by insulin and nutrient overload (e.g. amino acids (AA)), which leads to the inhibition of the PI3K/Akt pathway via the inhibitory serine phosphorylation of IRS-1, notably on serine 1101 (Ser-1101). However, even in the absence of AA, insulin can still promote IRS-1 Ser-1101 phosphorylation by other kinases that remain to be fully characterized. Here, we describe a new negative regulator of IRS-1, the p90 ribosomal S6 kinase (RSK). Computational analyses revealed that Ser-1101 within IRS-1 falls into the consensus motif of RSK. Moreover, recombinant RSK phosphorylated IRS-1 C-terminal fragment on Ser-1101, which was prevented by mutations of this site or when a kinase-inactive mutant of RSK was used. Using antibodies directed toward the phosphorylation sites located in the activation segment of RSK (Ser-221 or Ser-380), we found that insulin activates RSK in L6 myocytes in the absence of AA overload. Inhibition of RSK using either the pharmacological inhibitor BI-D1870 or after adenoviral expression of a dominant negative RSK1 mutant (RSK1-DN) showed that RSK selectively phosphorylates IRS-1 on Ser-1101. Accordingly, expression of the RSK1-DN mutant in L6 myocytes and FAO hepatic cells improved insulin action on glucose uptake and glucose production, respectively. Furthermore, RSK1 inhibition prevented insulin resistance in L6 myocytes chronically exposed to high glucose and high insulin. These results show that RSK is a novel regulator of insulin signaling and glucose metabolism and a potential mediator of insulin resistance, notably through the negative phosphorylation of IRS-1 on Ser-1101.
Collapse
Affiliation(s)
- Nicolas Smadja-Lamère
- From the Quebec Heart and Lung Institute, Laval University, 2705 Chemin Ste-Foy, Ste-Foy (Quebec) G1V4G5, Canada
| | | | | | | | | | | |
Collapse
|
25
|
Gallo-Payet N, Shum M, Baillargeon JP, Langlois MF, Wallinder C, Alterman M, Hallberg A, C. Carpentier A. AT2 Receptor Agonists: Exploiting the Beneficial Arm of Ang II Signaling. Curr Hypertens Rev 2012. [DOI: 10.2174/157340212800504990] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
26
|
Shum M, Bodofsky E, Skaff Z, El-Khoury M, Kankipati S, Dalsania C, Khemka V, Parra R, Dibiase S, Somer R. The incidence of prostate cancer in patients under the age of 60 from an urban setting. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14622 Background: Although the risk for developing prostate cancer increases with age, few studies have reported the incidence of prostate cancer in men younger than 60 from an urban setting. Methods: All patients diagnosed and treated for prostate cancer at The Cancer Institute of New Jersey at Cooper University Hospital in Camden County, New Jersey from January 1, 2004 to December 31, 2004 were retrospectively identified from our tumor registry. Age comparison at diagnosis was made utilizing the Cooper registry and the National Cancer Database (NCDB), 2001. Results: A total of 141 men (88 Caucasians, 37 African Americans, 14 Hispanic, and 6 unknown) with a median age of 64 years (range, 44–88 years) were diagnosed with prostate cancer in 2004. Staging revealed Stage II (118), Stage III (3), Stage IV (4), Stage unknown (16) cases. Median Gleason score was 6. 74 patients underwent radical prostatectomy, 50 had radiation, 30 received hormone therapy and 2 received chemotherapy. At diagnosis, 19.95% of the men were under 50 and 41.84% were under 60 years of age. Our dataset from these two age groups compared to NJ and US figures are noted below. Conclusions: When comparing the respective data sets from CINJ at Cooper to NJ and US utilizing the NCDB, there are striking differences with a higher incidence of prostate cancer in younger men. These incidences parallel those seen in other urban university teaching hospitals from the Healthcare Utilization Project (2005), where more patients under the age of 60 are being diagnosed with prostate cancer when compared to community centers. Subset analysis shows that our institution had a disproportionately larger number of African American men with prostate cancer which may relate to our culturally directed screening program, accounting for the higher incidence. These data support that hospital characteristics may impact age at diagnosis of prostate cancer, and further investigation is warranted. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Shum
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| | - E. Bodofsky
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| | - Z. Skaff
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| | - M. El-Khoury
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| | - S. Kankipati
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| | - C. Dalsania
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| | - V. Khemka
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| | - R. Parra
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| | - S. Dibiase
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| | - R. Somer
- Cancer Institute of New Jersey at Cooper University Hospital, Camden, NJ
| |
Collapse
|
27
|
Skaff Z, Hannigan K, Hughes S, Atabek U, Shum M, Kankipati S, Elkhoury M, Hageboutros A. Improved survival in patients with locally advanced esophageal cancer utilizing a multidisciplinary approach. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14130 Background: Locally advanced esophageal cancer studies have reported a three year overall survival rate of 32% with a median survival of 16 months. These patients were treated with combined chemotherapy and radiation with surgery, when applicable. We conducted this study to determine whether using an individualized, multidisciplinary approach affected survival outcomes in patients treated for locally advanced esophageal cancer. Methods: All patients treated for locally advanced esophageal cancer were retrospectively identified from our database at The Cancer Institute of New Jersey at Cooper University Hospital. All patients were presented and discussed in a multidisciplinary gastrointestinal tumor board conference. After a consensus was obtained, a treatment plan was established for each patient based on his or her respective clinical characteristics: stage, performance status, medical suitability for surgery and resectabilty. Results: A total of 23 patients (median age: 66 years [range, 55–88 years]) were identified, the histopathologic diagnosis was adenocarcinoma in 13 and squamous cell carcinoma in 10 cases. TNM staging was as follows: 18 (78.3%) stage II or III and 5 (21.7%) stage IV. Initial management included esophagectomy for 9 (39.1%), 6 of which received preoperative chemotherapy (5-FU) and three received postoperative adjuvant chemotherapy, 14 (60.9%) received only combined chemotherapy (average four cycles of 5FU 1000 mg per square meter of body surface + Cisplatin 75 mg per square meter of body surface) and radiation at doses 50–64 Gy. Overall median survival was not reached since only five patients (21.7%) have died. The 1- year and 2-year survival rates were 87% and 74% respectively. Median follow-up for patients who received combination chemotherapy and radiation vs. surgery with preoperative therapy was 29 and 41 months, respectively. Conclusion: This retrospective analysis shows promising outcomes compared to published data supporting the role of an individualized, multidisciplinary approach in the management of each patient with esophageal cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Z. Skaff
- Cancer Institute of New Jersey at Cooper Hospital, Voorhees, NJ
| | - K. Hannigan
- Cancer Institute of New Jersey at Cooper Hospital, Voorhees, NJ
| | - S. Hughes
- Cancer Institute of New Jersey at Cooper Hospital, Voorhees, NJ
| | - U. Atabek
- Cancer Institute of New Jersey at Cooper Hospital, Voorhees, NJ
| | - M. Shum
- Cancer Institute of New Jersey at Cooper Hospital, Voorhees, NJ
| | - S. Kankipati
- Cancer Institute of New Jersey at Cooper Hospital, Voorhees, NJ
| | - M. Elkhoury
- Cancer Institute of New Jersey at Cooper Hospital, Voorhees, NJ
| | - A. Hageboutros
- Cancer Institute of New Jersey at Cooper Hospital, Voorhees, NJ
| |
Collapse
|
28
|
Deubner D, Kelsh M, Shum M, Maier L, Kent M, Lau E. Beryllium Sensitization, Chronic Beryllium Disease, and Exposures at a Beryllium Mining and Extraction Facility. ACTA ACUST UNITED AC 2001; 16:579-92. [PMID: 11370937 DOI: 10.1080/104732201750169697] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
In this study, we examine beryllium sensitization, chronic beryllium disease (CBD), and workplace exposures at a beryllium mining (mine) and extraction facility (mill) in Delta, Utah. Historical airborne beryllium data collected between 1970-1999 included general area (GA), breathing zone (BZ), and personal lapel (LP) measurements and calculations of job-specific quarterly daily-weighted averages (DWVAs). We compared GA, BZ, and DWA data to airborne beryllium data from a mixed beryllium products facility and a beryllium ceramics facility located in Elmore, Ohio and Tucson, Arizona, respectively. At the Delta facility, jobs involving beryllium hydrolysis and wet-grinding activities had the highest air concentrations; annual median GA concentrations were less than 0.3 microg/m3 or both areas. Annual median GA sample concentrations ranged from 0.1-0.4 microg/m(-3) at Delta. These levels were generally lower than Elmore (0.1-1.0 microg/m3) and were comparable to the Tucson facility (0.1-0.4 microg/m3). Median BZ concentrations were higher, whereas DWAs were lower at the Delta facility than at the other two facilities. Among the 87 employees at the Delta facility, 75 participated in the medical survey; there were three persons sensitized, one with CBD. The individual with CBD previously worked at the Elmore facility for 10 years. Cumulative CBD incidence rates were significantly lower at the Delta facility: 0.3 percent compared to 2.0 percent for Elmore and 2.5 percent for the Tucson facility. Sensitization and CBD prevalence rates determined from cross-sectional surveys for the Delta facility were lower than but not significantly different from rates at the other two facilities. There was no sensitization or CBD among those who worked only at the mine where the only exposure to beryllium results from working with bertrandite ore. Although these results are derived from a small sample, this study suggests that the form of beryllium may affect the likelihood of developing CBD. Specifically, exposure to beryl and bertrandite ore dusts or to beryllium salts, in the absence of exposure to beryllium oxide particulates appears to pose a lower risk for developing CBD.
Collapse
Affiliation(s)
- D Deubner
- Brush Wellman Inc., Elmore, Ohio, USA
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
A survey was conducted of persons who manufacture, mix, bottle, and package methyl 2-cyanoacrylate (MCA) and ethyl 2-cyanoacrylate (ECA). Airborne concentrations of these cyanoacrylates also were measured during waste-handling operations. During a 1-week period, 162 personal and area samples were collected. About 90% of the samples were analyzed for ECA (the predominant adhesive being manufactured at the facility). About 50% of the samples were collected during periods of 15 min or less, the remainder for 15 to 240 min. Some 8-hour time-weighted average (TWA) samples also were collected. Samples were collected using Tenax tubes with subsequent analysis by high-performance liquid chromatography. Most samples were collected where highest exposure was likely (e.g., during mixing, bottling, and packaging). Peak concentrations of exposure (duration of 15 min or less), measured during a variety of tasks, ranged from 0.003 to 1.5 ppm. In particular, personal mean short-term airborne concentrations of ECA for the mixing operators ranged from 0.039 ppm to 0.650 ppm, while various 10-min to 1-hour activities were performed, with a TWA concentration of 0.07 ppm. Personal short-term airborne concentrations of ECA for bottling and packaging workers (n = 60) were 0.040 ppm +/- 0.016 ppm (mean +/- standard deviation), with similar 8-hour TWA concentrations due to the continuous nature of bottling and packaging. Other personal samples were not significantly different. The area samples were normally within a factor of 2 of the peak personal sampling results. These data indicate that, when handled at room temperature and relative humidity ranging from 40-69%, both MCA and ECA produce airborne concentrations that are nearly always less than about 0.1 ppm, which is less than the threshold of irritation.
Collapse
Affiliation(s)
- D Paustenbach
- Exponent Environmental Group, Menlo Park, CA 94025, USA
| | | | | | | |
Collapse
|
30
|
Shum M, Lavkulich L. Speciation and solubility relationships of Al, Cu and Fe in solutions associated with sulfuric acid leached mine waste rock. ACTA ACUST UNITED AC 1999. [DOI: 10.1007/s002540050401] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|